US FDA approves Outlook Therapeutics' eye disease drug
24/07/2026 19:42
US FDA approves Outlook Therapeutics' eye disease drug July 24 (Reuters) - The U.S. Food and Drug Administration on Friday approved Outlook Therapeutics' OTLK.O drug for a type of eye disease that can cause severe vision loss, the company said.
(Reporting by Kamal Choudhury and Sruthi Narasimha Chari in Bengaluru; Editing by Shilpi Majumdar)
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce